Clinical Trials Browser

Cholangiocarcinoma × futibatinib × 30 days × Clear all

NCT05727176 2026-05-28

FOENIX-CCA4

Phase 2 Recruiting

Gastrointestinal

Cholangiocarcinoma

NCT06506955 2026-05-28

Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.

Phase 2/3 Enrolling by invitation

Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma